
By: Phedon Nicolaides (Lexxion)
State aid should support outcomes that the market by itself cannot achieve. This implies that State aid that is restricted to only one or a few undertakings is unlikely to be capable of delivering the desired outcome. Yet, sometimes there may be good reasons for restricting the beneficiaries of State aid. On 29 April 2021, the Court of Justice dealt with this issue in case C‑847/19 P, Achemos Grupė & Achema v European Commission, concerning the direct award of a contract to the operator an LNG terminal in Lithuania.
The judgment of the Court is important because it highlights that essential national interests may justify deviation from the normal public procurement procedures.
Deviating from public procurement rules by, for example, awarding directly a contract, is always problematic from a State aid perspective because, by and large, it confers an advantage that may constitute State aid. By implication, State aid that violates other provisions of EU law, such as public procurement, makes it more difficult for that aid to be considered compatible with the internal market. However, as the Court confirmed in the Achemos case, the aid can be compatible if the direct award is necessitated by reasons of essential national interests which are recognised as an exemption from the requirements of public procurement directives.
Achemos and Achema appealed against the judgment of the General Court in case T-417/16, Achemos Grupė & Achema v European Commission. In that judgment the General Court dismissed their request for annulment of Commission decision SA.36740 which found aid granted by Lithuania to Klaipėdos Nafta compatible with the internal market. The judgment of the General Court was reviewed here on 8 October 2019…
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas